Warnex to Delay Release of its Financial Statements
(firmenpresse) - LAVAL, QUEBEC -- (Marketwire) -- 03/28/12 -- Warnex Inc. (TSX: WNX) ("Warnex") announces that the public filing of its audited consolidated financial statements for the financial year ended December 31, 2011 and the related Management's Discussion and Analysis, together with its 2012 Annual Information Form, originally scheduled to take place on March 30, 2012, will be delayed by approximately one week. This delay is attributable to the previously announced departure of Warnex's Chief Financial Officer and the time required for the orderly transition of his responsibilities so as to permit the proper completion of each of the foregoing.
About Warnex
Warnex () is a life sciences company devoted to protecting public health by providing laboratory services to the pharmaceutical sector. Warnex Analytical Services provides pharmaceutical and biotechnology companies with a variety of quality control services, including chemistry, chromatography, microbiology, method development and validation, and stability studies. Warnex Bioanalytical Services specializes in bioequivalence and bioavailability studies for clinical trials. Warnex has two facilities located in Laval and Blainville, Quebec.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For further information identifying known risks and uncertainties, relating to financial resources, liquidity risk, key customers and business partners, credit risk, foreign currency risk, government regulations, laboratory facilities, volatility of share price, employees, suppliers, and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Warnex's most recent Management's Discussion and Analysis, which can be found at . Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.
Contacts:
Michael Singer
Chairman of the Executive Committee
of the Board of Directors, Warnex Inc.
(514) 940-3610
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 28.03.2012 - 18:21 Uhr
Sprache: Deutsch
News-ID 129576
Anzahl Zeichen: 0
contact information:
Town:
LAVAL, QUEBEC
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 183 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Warnex to Delay Release of its Financial Statements"
steht unter der journalistisch-redaktionellen Verantwortung von
Warnex Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
